Treatment of Sinonasal Teratocarcinosarcoma: A case report

Abstract

Sinonasal teratocarcinosarcoma (SNTCS) is a rare malignancy characterized by a highly aggressive nature. Itmainly arises in the ethmoidal ormaxillary sinus. SNTCShas a poor prognosis, with a mean survival rate of 55% at 2 years. Herein, we presented a case of advanced SNTCS successfully treated with surgery followed by chemoradiotherapy plus targeted therapy and reviewed the published literature on this rare entity.

Keywords

chemotherapy / radiotherapy / Sinonasal Teratocarcinosarcoma / targeted therapy

References

[1] Peralta SuarezG, DibsK, CarrauRL, Schoenfield L, BlakajDM, TinocoG. Sinonasal teratocarcinosarcoma: a therapeutic dilemma. BMJ Case Rep. 2022;15(11):e252429.

[2] ChapurinN, TottenDJ, MorseJC, et al. Treatment of sinonasal teratocarcinosarcoma: a systematic review and survival analysis. Am J Rhinol Allergy. 2021;35(1):132-141.

[3] Krishna KumarK, Sundararajan I, RangachariV, SumathiV. Sinonasal teratocarcinosarcoma-A case report. Indian J Otolaryngol Head Neck Surg. 2007;59(2):148-150.

[4] QuYC, FULY, ZengDH, et al. Teratocarcinoma sarcoma of nasal cavity and paranasal sinuses: a case report. Chin J CT and MRI. 2015;13(9):118-120.

[5] ShiYY, ZhangY, ChengJL, et al. A case of paranasal sinus teratocarcinoma sarcoma involving the left frontal lobe. Chin J Interv Imaging Ther. 2018;15(7):451.

[6] MisraP, HusainQ, SviderPF, et al. Management of sinonasal teratocarcinosarcoma: a systematic review. Am J Otolaryngol. 2014;35(1):5-11.

[7] HeffnerDK, HyamsVJ. Teratocarcinosarcoma (malignant teratoma?) of the nasal cavity and paranasal sinuses: A clinicopathologic study of 20 cases. Cancer. 1984;53(10):2140-2154.

[8] WangY, SunXJ, et al. Imaging analysis and literature review of sinonasal teratocarcinosarcoma:report of one case. J Chin Clin Med Imag. 2022;33(3):221-223.

[9] WangSY, LiSM, et al. Pathological features and diagnosis of teratocarcinoma sarcoma in nasal cavity and paranasal sinuses. Chin J Pathol. 2007;36(8):534-538.

[10] SableM, KakkarA, GargK, et al. Sinonasal teratocarcinosarcoma: an underdiagnosed entity posing diagnostic challenges. Turk Neurosurg. 2017;27(3):468-471.

[11] BirkelandAC, BurginSJ, YanikM, et al. Pathogenetic analysis of sinonasal teratocarcinosarcomas reveal actionable β-catenin overexpression and a β-catenin mutation. J Neurol Surg B Skull Base. 2017;78(4):346-352.

[12] RooperLM, UddinN, GaganJ, et al. Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma. Am J Surg Pathol. 2020;44(10):1331-1339.

[13] ShenG, ZhengF, RenD, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120.

[14] LeeNY, Terezakis SA. Intensity-modulated radiation therapy. J Surg Oncol. 2008;97(8):691-696.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.